ClinicalTrials.gg
RecruitingNCT06892249Updated Oct 1, 2026

Suitability of a High-energy, Low-protein Formula (Renalive® LP)

An interventional study of Renalive® LP, in CKD, Low Protein Dietary Intake and Malnutrition (Calorie), sponsored by Fresenius Kabi Taiwan Ltd.. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fresenius Kabi Taiwan Ltd. (part of Fresenius Kabi) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Malnutrition by Fresenius Kabi — 4 open to participants now, 4 under way, none of them phase 3. Malnutrition · Fresenius Kabi.

Started
2025
with 1 other
No phase
4 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Malnutrition by Fresenius Kabi, this one is one of 2 that started in 2025, is one of 4 with no phase, and was the 12th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

4 of the 13 studies in Malnutrition by Fresenius Kabi are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Malnutrition by Fresenius Kabi, or all of them as a file.
02

Study summary

Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2)

Exclusion criteria

(1) Has received dialysis or are expected to start dialysis within the next 3 months.

03

Conditions studied

  • CKD
  • Low Protein Dietary Intake
  • Malnutrition (Calorie)

Browse trials for

04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(1) Diagnosed with chronic kidney disease stage 3b-5 (with history of \<45 mL/min/1.73 m2)

Exclusion criteria

Exclusion Criteria:

(1) Has received dialysis or are expected to start dialysis within the next 3 months

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Renalive® LP

    Dietary Supplement: Renalive® LP,

Interventions

  • Dietary supplementRenalive® LP,

    flavour

06

What researchers measure

Primary outcomes

  1. Change in body weight from Baseline to end of treatment at Week 4 (Week 4 - Baseline)

    Time frame: 4 weeks

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 419 interventional studies with no phase under Malnutrition, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 30 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Apr 2026 → Dec 2027 and completion Apr 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 24, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Dec 31, 2027was Apr 2026
CompletionEst.
Dec 31, 2027was Apr 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Sep 28, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Kaosiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwanno status→Recruiting
  • Taipei TzuChi Hospital · New Taipei City, Taiwanno status→Recruiting
Sep 28, 2026
Primary completion
Apr 21, 2026→Dec 31, 2027
Sep 28, 2026
Study completion
Apr 21, 2026→Dec 31, 2027
Sep 28, 2026
Enrollment
74 (actual)→80 (estimated)
Sep 28, 2026
Eligibility
Criteria largely rewritten (18 changes)
What changed in the criteria
Inclusion criteria
  • RemovedAge: ≥18 years
  • RemovedOutpatients with instruction to keep a low protein diet (0.55-0.8 g protein /kg actual body weight/ day) in the last 3 months as evaluated by the Investigator
  • RemovedWritten Informed Consent from patient
Exclusion criteria
  • RemovedPatients awaiting kidney transplant
  • RemovedBody mass index (BMI) <18 kg/m2 or BMI >30 kg/m2
  • RemovedMalnourished patients with albumin <3 g/dL in need of extra calories and nutrients
  • RemovedPatients receiving or having received oral/enteral/parenteral nutrition supplementation for special medical purpose in the last 7 days
  • RemovedSevere liver disease, malignant neoplastic disease, current significant infectious disease (apart from flu, cold, Hepatitis C virus (HCV) carrier, Hepatitis B virus (HBV) carrier, skin infection) deemed unsuitable for entering the trial as evaluated by the Investigator
  • RemovedExisting gastrointestinal disease or pathological findings that cannot tolerate enteral nutrition or render enteral nutrition unfeasible, such as shock, acute upper gastrointestinal bleeding, intestinal sluggishness, intestinal obstruction, or malabsorption, such as inflammatory bowel disease, pancreatic disease, or gastrointestinal surgery
  • RemovedSevere impairment of gastrointestinal function, i.e. severe constipation or acute diarrhoea (≥3 loose or watery stools a day)
  • RemovedSwallowing difficulty or high risk of aspiration
  • RemovedCentral nervous system and/or certain psychiatric disorders where the patient is considered as not yet clinically stable and/or not suitable to participate in this study by the Investigator
  • RemovedKnown allergic reaction or intolerance to any ingredient of the intervention formula
  • RemovedSurgery or hospitalization scheduled during the trial
  • RemovedSuspected drug abuse
  • RemovedUnable to follow study instructions or keep a dietary diary
  • RemovedPregnant or lactating women
  • RemovedParticipation in other clinical trials using investigational drugs within 30 days before the start of the trial or during the trial.
Sep 28, 2026
Interventions
Changed Renalive® LP, flavour Vanilla→Renalive® LP,. Removed Dietary supplement: Renalive® LP, flavour Cappuccino
Sep 28, 2026
Secondary outcomes
10 removed
What changed in the outcomes
  • RemovedDaily dietary intake of energy, protein, sodium, potassium, magnesium, phosphorus, and calcium at Baseline, Week 2 and 4 based on a 3-Day Dietary RecordTime frame: 4 weeks
  • RemovedChange in body weight from Baseline to Week 2Time frame: 2 weeks
  • RemovedChange in BMI from Baseline to Week 2 and Week 4Time frame: 4 weeks
  • RemovedChange of the physical performance using hand grip strength as an indicator from Baseline to Week 4Time frame: 4 weeks
  • RemovedChange in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) from Baseline to Week 4Time frame: 4 weeks
  • RemovedChange in blood urea nitrogen and serum creatinine from Baseline to Week 2 and week 4Time frame: 4 weeks
  • RemovedSerum albumin and pre-albumin at Baseline and Week 4Time frame: 4 weeks
  • RemovedBlood electrolytes (sodium, potassium, phosphorus, calcium, magnesium) at Baseline, Week 2 and 4Time frame: 4 weeks
  • RemovedSerum C-reactive protein (CRP) at Baseline, Week 2 and 4Time frame: 4 weeks
  • RemovedCompliance rate (%) to Renalive® LPTime frame: 4 weeks
Sep 28, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Kaosiung Chang Gung Memorial Hospital · Kaohsiung City, TaiwanContact added c•••@cgmh.org.tw
  • Taipei TzuChi Hospital · New Taipei City, TaiwanContact added w•••@hotmail.com · •••9779
Sep 28, 2026
Title
Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Completed→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Kaosiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwanno status→Recruiting
    • Taipei TzuChi Hospital · New Taipei City, Taiwanno status→Recruiting
    Primary completion Apr 21, 2026→Dec 31, 2027
    Study completion Apr 21, 2026→Dec 31, 2027
    Enrollment 74 (actual)→80 (estimated)
    Eligibility Criteria largely rewritten (18 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedAge: ≥18 years
    • RemovedOutpatients with instruction to keep a low protein diet (0.55-0.8 g protein /kg actual body weight/ day) in the last 3 months as evaluated by the Investigator
    • RemovedWritten Informed Consent from patient
    Exclusion criteria
    • RemovedPatients awaiting kidney transplant
    • RemovedBody mass index (BMI) <18 kg/m2 or BMI >30 kg/m2
    • RemovedMalnourished patients with albumin <3 g/dL in need of extra calories and nutrients
    • RemovedPatients receiving or having received oral/enteral/parenteral nutrition supplementation for special medical purpose in the last 7 days
    • RemovedSevere liver disease, malignant neoplastic disease, current significant infectious disease (apart from flu, cold, Hepatitis C virus (HCV) carrier, Hepatitis B virus (HBV) carrier, skin infection) deemed unsuitable for entering the trial as evaluated by the Investigator
    • RemovedExisting gastrointestinal disease or pathological findings that cannot tolerate enteral nutrition or render enteral nutrition unfeasible, such as shock, acute upper gastrointestinal bleeding, intestinal sluggishness, intestinal obstruction, or malabsorption, such as inflammatory bowel disease, pancreatic disease, or gastrointestinal surgery
    • RemovedSevere impairment of gastrointestinal function, i.e. severe constipation or acute diarrhoea (≥3 loose or watery stools a day)
    • RemovedSwallowing difficulty or high risk of aspiration
    • RemovedCentral nervous system and/or certain psychiatric disorders where the patient is considered as not yet clinically stable and/or not suitable to participate in this study by the Investigator
    • RemovedKnown allergic reaction or intolerance to any ingredient of the intervention formula
    • RemovedSurgery or hospitalization scheduled during the trial
    • RemovedSuspected drug abuse
    • RemovedUnable to follow study instructions or keep a dietary diary
    • RemovedPregnant or lactating women
    • RemovedParticipation in other clinical trials using investigational drugs within 30 days before the start of the trial or during the trial.
    Secondary outcomes 10 removed
    What changed in the outcomes
    • RemovedDaily dietary intake of energy, protein, sodium, potassium, magnesium, phosphorus, and calcium at Baseline, Week 2 and 4 based on a 3-Day Dietary RecordTime frame: 4 weeks
    • RemovedChange in body weight from Baseline to Week 2Time frame: 2 weeks
    • RemovedChange in BMI from Baseline to Week 2 and Week 4Time frame: 4 weeks
    • RemovedChange of the physical performance using hand grip strength as an indicator from Baseline to Week 4Time frame: 4 weeks
    • RemovedChange in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) from Baseline to Week 4Time frame: 4 weeks
    • RemovedChange in blood urea nitrogen and serum creatinine from Baseline to Week 2 and week 4Time frame: 4 weeks
    • RemovedSerum albumin and pre-albumin at Baseline and Week 4Time frame: 4 weeks
    • RemovedBlood electrolytes (sodium, potassium, phosphorus, calcium, magnesium) at Baseline, Week 2 and 4Time frame: 4 weeks
    • RemovedSerum C-reactive protein (CRP) at Baseline, Week 2 and 4Time frame: 4 weeks
    • RemovedCompliance rate (%) to Renalive® LPTime frame: 4 weeks
    Interventions Changed Renalive® LP, flavour Vanilla→Renalive® LP,. Removed Dietary supplement: Renalive® LP, flavour Cappuccino
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Kaosiung Chang Gung Memorial Hospital · Kaohsiung City, TaiwanContact added c•••@cgmh.org.tw
    • Taipei TzuChi Hospital · New Taipei City, TaiwanContact added w•••@hotmail.com · •••9779
    Title Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06892249
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Jun 4, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion